Literature DB >> 30363469

Topography of Dopamine Transporter Availability in the Cerebellar Variant of Multiple System Atrophy.

Michael Nocker1, Klaus Seppi1, Sylvia Boesch1, Eveline Donnemiller2, Irene Virgolini2, Gregor K Wenning1, Werner Poewe1, Christoph Scherfler1.   

Abstract

BACKGROUND: Voxel-wise comparison of [123I]-2β-carbomethoxy-3beta-(4-iodophenyl)tropane ([123I]β-CIT) radioligand distribution measured by single-photon emission computed tomography (SPECT) revealed distinct patterns of reduced dopamine transporter (DAT) availability in the Parkinson's variant of MSA (MSA-P). The aim of this study was to identify the monoamine transporter distribution pattern in patients with the cerebellar variant of MSA (MSA-C). Additionally, monoamine transporter availability was investigated in a small cohort of patients with sporadic adult-onset ataxia (SAOA).
METHODS: [123I]β-CIT SPECT was performed in patients with MSA-C (n = 12), MSA-P (n = 14), SAOA (n = 5), and controls (n = 15) matched for age. Parametric images of [123I]β-CIT binding potential (BPND) were generated and analyzed by statistical parametric mapping (SPM) and region of interest (ROI) analysis.
RESULTS: SPM localized significant reductions of [123I]β-CIT BPND in the striatum, midbrain, and pons in MSA-C compared to controls. When compared with MSA-P, the striatal DAT decline was significantly less affected in MSA-C. ROI analysis revealed reductions of striatal and midbrain [123I]β-CIT binding in MSA-C compared to SAOA, whereas no significant difference was apparent between the SAOA and control groups.
CONCLUSIONS: Midbrain and pontine monoaminergic transporter binding was severely impaired in MSA-C, matching the underlying pathological features. Striatal DAT availability was relatively less affected in MSA-C compared to MSA-P, reflecting measureable, but less-profound, degeneration of the nigrostriatal dopaminergic projections. Preliminary results of reduced striatal and midbrain [123I]β-CIT binding in MSA-C, compared to SAOA, suggest that the potential of DAT-SPECT as a surrogate marker in the diagnostic workup of patients with adult-onset cerebellar ataxia should be further investigated.

Entities:  

Keywords:  dopamine transporter; multiple system atrophy; sporadic adult‐onset ataxia; voxel based analysis

Year:  2016        PMID: 30363469      PMCID: PMC6174450          DOI: 10.1002/mdc3.12446

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  41 in total

1.  Brain monoamine systems in multiple system atrophy: a positron emission tomography study.

Authors:  Stephanie J Lewis; Nicola Pavese; Maria Rivero-Bosch; Karla Eggert; Wolfgang Oertel; Christopher J Mathias; David J Brooks; Alex Gerhard
Journal:  Neurobiol Dis       Date:  2012-01-12       Impact factor: 5.996

2.  A unified statistical approach for determining significant signals in images of cerebral activation.

Authors:  K J Worsley; S Marrett; P Neelin; A C Vandal; K J Friston; A C Evans
Journal:  Hum Brain Mapp       Date:  1996       Impact factor: 5.038

Review 3.  Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Authors:  Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-09       Impact factor: 6.200

4.  Clinical features and natural history of multiple system atrophy. An analysis of 100 cases.

Authors:  G K Wenning; Y Ben Shlomo; M Magalhães; S E Daniel; N P Quinn
Journal:  Brain       Date:  1994-08       Impact factor: 13.501

5.  Decreased striatal monoaminergic terminals in multiple system atrophy detected with positron emission tomography.

Authors:  S Gilman; R A Koeppe; L Junck; R Little; K J Kluin; M Heumann; S Martorello; J Johanns
Journal:  Ann Neurol       Date:  1999-06       Impact factor: 10.422

6.  beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo.

Authors:  W Pirker; S Asenbaum; S Kasper; H Walter; P Angelberger; G Koch; A Pozzera; L Deecke; I Podreka; T Brücke
Journal:  J Neural Transm Gen Sect       Date:  1995

7.  Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome).

Authors:  M I Papp; J E Kahn; P L Lantos
Journal:  J Neurol Sci       Date:  1989-12       Impact factor: 3.181

8.  Second consensus statement on the diagnosis of multiple system atrophy.

Authors:  S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet
Journal:  Neurology       Date:  2008-08-26       Impact factor: 9.910

9.  Distribution of cerebello-olivary degeneration in idiopathic late cortical cerebellar atrophy: clinicopathological study of four autopsy cases.

Authors:  Satoru Ota; Kuniaki Tsuchiya; Midori Anno; Kazuhiro Niizato; Haruhiko Akiyama
Journal:  Neuropathology       Date:  2008-02       Impact factor: 1.906

10.  [3H]GBR 12935 binding to dopamine uptake sites in the human brain.

Authors:  J De Keyser; J P De Backer; G Ebinger; G Vauquelin
Journal:  J Neurochem       Date:  1989-11       Impact factor: 5.372

View more
  1 in total

Review 1.  Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group.

Authors:  Maria Teresa Pellecchia; Iva Stankovic; Alessandra Fanciulli; Florian Krismer; Wassilios G Meissner; Jose-Alberto Palma; Jalesh N Panicker; Klaus Seppi; Gregor K Wenning
Journal:  Mov Disord Clin Pract       Date:  2020-09-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.